Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2019-2020, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolf, P. L.
Right arrow Articles by Mercola, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolf, P. L.
Right arrow Articles by Mercola, D.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 1997;43:2019-2020.)
© 1997 American Association for Clinical Chemistry, Inc.

Editorials

The Cloning Debates and Progress in Biotechnology

Paul L. Wolf1,a, George Liggins2 and Dan Mercola3

1 Department of Pathology, University of California and Veterans Affairs Medical Centers, 200 W. Arbor Drive, San Diego, CA 92103, Fax 619-552-7452,

2 Bacton Assay Systems, Inc., San Marcos, CA 92069, e-mail docliggins@aol.com

3 Sidney Kimmel Cancer Center, San Diego, CA 92121, and, Center for Molecular Genetics, University of California–San Diego, La Jolla, CA 92093, Fax 619-450-3251
a Author for correspondence

The perception by humans of what is doable is itself a great determiner of future events. Thus, the successful sheep cloning experiment leading to "Dolly" by Ian Wilmut and associates at Roslin Institute, Midlothian, UK, compels us to look in the mirror and consider the issue of human cloning. Should it occur, and if not, how should that opposing mandate be managed? If human cloning should have an acceptable role, what is that role and how should it be monitored and supervised?

In the February 27, 1997, issue of Nature, Ian Wilmut et al. reported that they cloned a sheep (which they named "Dolly") by transferring the nuclear DNA from an adult sheep udder cell into an egg whose DNA had been removed (1). Their cloning experiments have led to widespread debate on the potential application of this remarkable technique to the cloning of humans. Following the Scottish researchers' startling report, President Clinton declared his opposition to using this technique to clone humans. He moved swiftly to order that federal funds not be used for such an experiment and asked an independent panel of experts, the National Bioethics Advisory Commission (NBAC), chaired by Princeton University President Harold Shapiro, to report to the White House with recommendations for a national policy on human cloning. According to recommendations by the NBAC, human cloning is likely to become a crime in the US in the near future. The Commission's main recommendation is to enact federal legislation to prohibit any attempts, whether in a research or a clinical setting, to create a human through somatic cell nuclear transfer cloning.

The concept of genetic manipulation is not new and has been a general practice for more than a . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.